Health Economics and Outcomes Research Ltd, Cardiff, UK ; Centre for Health Economics, Swansea University, Swansea, UK.
Health Economics and Outcomes Research Ltd, Cardiff, UK.
Cost Eff Resour Alloc. 2015 Aug 4;13:12. doi: 10.1186/s12962-015-0038-8. eCollection 2015.
For end-users of diabetes models that include UKPDS 82 risk equations, an important question is how well these new equations perform. Consequently, the principal objective of this study was to validate the UKPDS 82 risk equations, embedded within an established type 2 diabetes mellitus (T2DM) model, the Cardiff Diabetes Model, to contemporary T2DM outcomes studies.
A total of 100 validation endpoints were simulated across treatment arms of twelve pivotal T2DM outcomes studies, simulation cohorts representing each validation study's cohort profile were generated and intensive and conventional treatment arms were defined in the Cardiff Diabetes Model.
Overall the validation coefficient of determination was similar between both sets of risk equations: UKPDS 68, R(2) = 0.851; UKPDS 82, R(2) = 0.870. Results stratified by internal and external validation studies produced MAPE of 43.77 and 37.82%, respectively, when using UKPDS 82, and MAPE of 40.49 and 53.92%, respectively when using UKPDS 68. Areas of lack of fit, as measured by MAPE were inconsistent between sets of equations with ACCORD demonstrating a noteworthy lack of fit with UKPPDS 68 (MAPE = 170.88%) and the ADDITION study for UKPDS 82 (MAPE = 89.90%).
This study has demonstrated that the UKPDS 82 equations exhibit similar levels of external validity to the UKPDS 68 equations with the additional benefit of enabling more diabetes related endpoints to be modeled.
对于包含 UKPDS 82 风险方程的糖尿病模型的终端用户来说,一个重要的问题是这些新方程的表现如何。因此,这项研究的主要目的是验证 UKPDS 82 风险方程,这些方程嵌入在一个已建立的 2 型糖尿病(T2DM)模型——卡迪夫糖尿病模型中,以验证当代 T2DM 结局研究。
在 12 项 T2DM 结局研究的治疗组中模拟了总共 100 个验证终点,为每个验证研究的队列概况生成了模拟队列,并在卡迪夫糖尿病模型中定义了强化治疗组和常规治疗组。
总体而言,两组风险方程的验证决定系数相似:UKPDS 68,R²=0.851;UKPDS 82,R²=0.870。按内部和外部验证研究分层的结果,当使用 UKPDS 82 时,MAPE 分别为 43.77%和 37.82%,当使用 UKPDS 68 时,MAPE 分别为 40.49%和 53.92%。作为衡量不拟合程度的指标,MAPE 在两组方程之间不一致,ACCORD 研究结果显示 UKPPDS 68(MAPE=170.88%)和 ADDITION 研究结果显示 UKPDS 82(MAPE=89.90%)的不拟合程度显著。
这项研究表明,与 UKPDS 68 方程相比,UKPDS 82 方程具有相似的外部有效性,并且具有能够对更多与糖尿病相关的终点进行建模的额外优势。